Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer-Reference-Cited by-同舟云学术

Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer

Published:2024-08-02 Issue:1 Volume:15 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Plumber Sakina A.^ORCID,Tate Tiffany,Al-Ahmadie Hikmat^ORCID,Chen Xiao,Choi Woonyoung^ORCID,Basar Merve,Lu Chao^ORCID,Viny Aaron^ORCID,Batourina Ekatherina,Li Jiaqi,Gretarsson Kristjan^ORCID,Alija Besmira,Molotkov Andrei,Wiessner Gregory,Lee Byron Hing Lung,McKiernan James,McConkey David J.^ORCID,Dinney Colin,Czerniak Bogdan^ORCID,Mendelsohn Cathy Lee^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41467-024-50678-2.pdf

Reference84 articles.

1. Dogliotti, L. et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur. Urol. 52, 134–141 (2007).

2. Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420–433 (2020).

3. Modi, P. K., Komaravelli, N., Singh, N. & Sharma, P. Interplay between MEK-ERK signaling, cyclin D1, and cyclin-dependent kinase 5 regulates cell cycle reentry and apoptosis of neurons. Mol. Biol. Cell 23, 3722–3730 (2012).

4. National Cancer Institute Surveillance, S., & End Results Program. Cancer Stat Facts: Bladder Cancer, https://seer.cancer.gov/statfacts/html/urinb.html (2022).

5. Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466–465 (2006).